Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России
Список исп. литературыСкрыть список 1. Беккер Р.А., Быков Ю. В. Флувоксамин: антидепрессант широкого спектра с рядом особенностей и преимуществ (обзор литературы). Психиатрия и психофармакотерапия. 2019; 01: 11–26. [in Russian]. 2. Волель Б.А. Современные психофармакологические подходы в лечении обсессивно-компульсивных расстройств. Психиатрия и психофармакотерапия. 2002; 4 (3): 104–106. / Volel’ B.A. Sovremennye psikhofarmakologicheskie podkhody v lechenii obsessivno-kompulsivnykh rasstroystv / B.A. Volel. Psikhiatriya i psykhofarmakoterapiya. 2002; 4(3): 104–106. [in Russian]. 3. Граненов Г.М., Мосолов С.Н. Применение антидепрессантов различных групп при терапии обсессивно-компульсивного расстройства. Журн. неврол. и психиатр. им. С.С. Корсакова. 2003: 7: 70–74. / Granenov G.M., Mosolov S.N. Primeneniye antidepressantov razlichnykh grupp pri terapii obsessivno-kompulsivnogo rasstroystva. Zhurn. Nevrol. i psikhiatr. im. S.S. Korsakova. 2003; 7: 70-74. [in Russian]. 4. Кутлубаев М.А. Роль лобно-подкорковых связей в развитии обсессивно-компульсивных расстройств / М.А. Кутлубаев. Неврология, нейропсихиатрия, психосоматика. 2016; 8 (2): 107–112. / Kutlubaev M.A. Rol’ lobno-podkorkovych svyazey v razvitii obsessivno-kompulsivnykh rasstroystv. Nevrologiya, neyropsikhiatriya, psikhosomatika. 2016; 8(2): 107–112. [in Russian]. 5. Медведев В.Э. Флувоксамин (феварин) в терапии расстройств обсессивно-компульсивного спектра. Психиатрия и психофармакотерапия. 2015; 17 (1): 44–49. / Medvedev V.E. Fluvoksamin (fevarin) v terapii rassroystv obsessivno-kompulsivnogo spectra. Psikhiatriya i psykhofarmakoterapiya. 2015; 17(1): 44–49 [in Russian]. 6. Морозов П.В., Павличенко А.В. Классификации психических расстройств, Психиатрия. Национальное руководство. Краткая версия. 2-е издание, М., «ГЕОТАР-Медиа», 2020 (в печати) 7. Морозов П.В., Петрова Н.Н. О подходах к терапии и предупреждению обсессивно-компульсивных расстройств (ОКР) в период пандемии COVID-19 (обзор международных рекомендациий). Психиатрия и психофармакотерапия им. П. Б. Ганнушкина. 2020; 2: 37–40. [in Russian]. 8. Мосолов С.Н. Обсессивно-компульсивное расстройство (диагностика, клиника, терапия): монография. М.: 2005: 56 c. / Mosolov S.N. Obsessivno-kompulsivnoe rasstroystvo (diagnostika, klinika, terapiya): monogpafiya. – М., 2005: 56 s. [in Russian]. 9. Мосолов С.Н., Алфимов П.В. Алгоритм биологической терапии обсессивно-компульсивного расстройства. Современная терапия психических расстройств. 2013; 1: 41–44. / Mosolov S.N., Alfimov P.V. Algoritm terapii obsessivno-kompulsivnogo rasstroystva. Sovremennaya terapiya psikhicheskikh rasstroystv. 2013; 1: 41–44. [in Russian]. 10. Проект клинических рекомендаций «Обсессивно-компульсивное расстройство (F42)». https://psychiatr.ru/news/1056 (свободный доступ). / Proekt klinicheskikh rekomendatsyy «Obsessivno-kompulsivnoe rasstroystvo (F42)». https://psychiatr.ru/news/1056 (svobodnyy dostup). [in Russian]. 11. Психические расстройства и расстройства поведения (F00-F99). (Класс V МКБ-10, адаптированный для использования в Российской Федерации). Под общей редакцией Б.А. Казаковцева, В.Б. Голланда. — М.: Минздрав России, 1998. / Psikhicheskie rasstroystva I rasstroystva povedeniya (F00-F99). (Klass V MKB-10, adaptirovannyy dlya ispolzovaniya v Rossiyskoy Federatsii). Pod obshchey redaktsiey B.A. Kazakovtseva, V.B. Gollanda. – M.: Minzdrav Rossii, 1998. [in Russian]. 12. Amir N., Freshman M., Foa E.B. Family distress and involvement in relatives of obsessive-compulsive disorder patients. J. Anxiety Disord. 2000; 14: 209-217. 13. Bandelow B., Sher L., Bunevicius R. et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive – compulsive disorder and posttraumatic stress disorder in primary care. International Journal of Psychiatry in Clinical Practice. 2012; 16: 77–84. 14. Cheyette S.R., Cummings J.L. Encephalitis lethargica: lessons for contemporary neuropsychiatry. J. Neuropsychiat. Clin. Neurosci. 1995; 7: 125–135. 15. Dell’Osso B., Nestadt G., Allen A. et al. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review. The Journal of Clinical Psychiatry. 2006; 67(4): 600–610. 16. Denys D., van der Wee N., Janssen J. et al. Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder. Biol. Psychiat. 2004; 55: 1041–1045. 17. DeVeaugh-Geiss J., Katz R., Landau P. et al. Clomipramine in the treatment of patients with obsessive-compulsive disorder: the clomipramine collaborative study group. Archs Gen. Psychiat. 1991; 48: 730–738. 18. Dold M., Aigner M., Lanzenberger R. et al. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. The International Journal of Neuropsychopharmacology. 2015; 18(9). 19. Fernandez-Cordoba E., Lopez-Ibor Alino J. La monoclorimipramina en enfermos psiquiatricos resistentes a otros tratamientos. Acta Luso-Esp. Neurol. Psiquiat. Ciene Afines. 1967; 26: 119–147. 20. Fineberg N.A., Van Ameringen M., Drummond L. et al. How to manage obsessive-compulsive disorder (OCD) under COVID-19: A clinician's guide from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of the European College of Neuropsychopharmacology. Comprehensive Psychiatry. Volume 100, July 2020, 152174. https://doi.org/10.1016/j.comppsych.2020.152174. 21. Fineberg N.A., Gale T.M. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int. J. Neuropsychopharmacol. 2005; 8: 107–129. 22. Giedd J.N., Rapoport J.L., Garvey M.A. MRI assessment of children with obsessive-compulsive disorder or tics associated with streptococcal infection. Am. J. Psychiat. 2000; 157: 281–283. 23. Goodman W.K., Price L.H., Rasmussen S.A. et al. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Archs. Gen. Psychiat. 1989; 46: 36-44. 24. Goodman W.K., Kozak M.J., Liebowitz M. et al. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicenter, double-blind, placebo-controlled trial. Int. Clin. Psychopharmacol. 1996; 11: 21-29. 25. 25.Hasanpour Н., Ghavamizadeh M, Navi К. et al. Fluvoxamine treatment response prediction in obsessive-compulsive disorder: association rule mining approach, Neuropsychiatr Dis Treat. 2019; 15: 895–904. 26. Hazari N., Narayanaswamy J.C., Venkatasubramanian G. Neuroimaging findings in obsessive-compulsive disorder: A narrative review to elucidate neurobiological underpinnings. Indian J Psychiatry. 2019; 61 (Suppl 1): S9-S29. doi: 10.4103/psychiatry.IndianJPsychiatry_525_18. 27. Hollander E., Koran L.M., Goodman W.K. et al. A double-blind placebo-controlled study of the efficacy and safety of controlled release fluvoxamine in patients with obsessive-compulsive disorder. J. Clin. Psychiat. 2003; 64: 640–647. 28. Hollander E., Stein D.J., Broatch J. et al. A pharmacoeconomic and quality of quality of life study of obsessive-compulsive disorder. CNS Spectrum. 1997; 2: 16–25. 29. ICD-11for mortality and morbidity statistics (2018). https://icd.who.int/ browse11/l-m/en - сайт ВОЗ, свободный доступ. 30. Issary Y., Jakubovski E., Bartley C.A. et al. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis The Journal of Clinical Psychiatry. 2016;77(5):e605-e611. 31. Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Ed. by C. Pettinger. New York: Oxford university press, 2017. DOI: 10.1093/med/9780190228163.001.0001. 32. Ozaki N., Goldman D., Kaye W.H. et al. Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol. Psychiat. 2003; 8: 895, 933–936. 33. Perse T., Greist J.H., Jefferson J.W. et al. Fluvoxamine treatment of obsessive-compulsive disorder. Am. J. Psychiat. 1987; 144: 1543–1548. 34. Purcell R., Maruff P., Kyrios M. et al. Cognitive deficits in obsessive-compulsive disorder on test of frontal-striatal function. Biol. Psychiat. 1998; 43: 348–357. 35. Riddle M.A., Reeve E.A., Yaryura-Tobias J. et al. Fluvoxamine for children and adolescent with obsessive-compulsive disorder; a randomized, controlled multicenter trial. J Am. Acad. of Child. Adolesc. Psychiat. 2001; 40: 222–229. 36. Skapinakis P. Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2016; 3(8): 730–739. 37. Soomro G.M., Altman D., Rajagopal S. et al. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD) Cochrane Database of Systematic Reviews. 2008; 1: CD001765. 38. Stein D.J., Stone M.H. Essential papers on obsessive-compulsive disorders. New York University Press, New York. 1997. 39. Stein D.J. Seminar on obsessive-compulsive disorder. Lancet. 2002; 360: 397–405. 40. Stein D.J., Fineberg N.A. Obsessive-compulsive disorder. New York: Oxford university press, 2007; 154 p. 41. Talbot P.S. The molecular neuroimaging of anxiety disorders. Cur. Psychiat. Rep. 2004; 6: 274–279. 42. Whiteside S.P., Port J.D., Abramowitz J.S. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiat. Res. 2004; 132: 69–79. 43. Wilson R, Nicely S, Quinlan K. Managing COVID-19 concerns for people with OCD. Five strategies for helping patients during the COVID-19 public health crisis. 2020: April 10. 44. Zohar J., Insel T.R. Drug treatment of obsessive-compulsive disorder. J. Affect. Disord. 1987; 13: 193–202. 45. Zohar J., Insel T.R., Zohar-Kadouch R.C. Serotoninergic responsivity in obsessive-compulsive disorder: effects of chronic clomipramine treatment. Archs Gen. Psychiat. 1988; 45: 167–172. 46. Smith S.B., Su T.-P. (eds.), Sigma Receptors: Their Role in Disease and as Therapeutic Targets, 2017, Advances in Experimental Medicine and Biology 964, DOI 10.1007/978-3-319-50174-1_11. 47. Hafeez ZH. Resolution of Pathological Skin Picking With Fluvoxamine in a 74-Year-Old Dementia Patient. Prim Care Companion CNS Disord. 2016; 18(1). doi: 10.4088/PCC.15l01844. 48. Fullana M.A., Abramovitch A., Via E. et al., Diagnostic biomarkers for obsessive-compulsive disorder: A reasonable quest or ignis fatuus? Neuroscience & Biobehavioral Reviews, August 2020, doi: 10.1016/j.neubiorev.2020.08.008.